Literature DB >> 16702880

Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease.

Haoyue Zhang1, Helmut Kallwass, Sarah P Young, Cortney Carr, Jian Dai, Priya S Kishnani, David S Millington, Joan Keutzer, Yuan-Tsong Chen, Deeksha Bali.   

Abstract

PURPOSE: The study's purpose was to compare acarbose and maltose as inhibitors of maltase-glucoamylase activity for determining acid alpha-glucosidase activity in dried blood spot specimens for early identification of patients with infantile Pompe disease, a severe form of acid alpha-glucosidase deficiency.
METHODS: Acid alpha-glucosidase activities in dried blood spot extracts were determined fluorometrically using the artificial substrate 4-methylumbelliferyl-alpha-D-pyranoside. Acarbose or maltose was used to inhibit maltase-glucoamylase, an enzyme present in polymorphonuclear neutrophils that contributes to the total alpha-glucosidase activity at acidic pH.
RESULTS: Complete discrimination between patients with proven infantile Pompe disease (n = 20), obligate heterozygotes (n = 16), and controls (n = 150) was achieved using 8 micromol/L acarbose as the inhibitor. Higher acarbose concentration (80 micromol/L) did not improve the assay. By using 4 mM maltose as the inhibitor, heterozygotes and patients were not completely separated. The results using acarbose compared well with those using the skin fibroblast assay in the same group of patients with proven infantile Pompe disease.
CONCLUSION: Acid alpha-glucosidase activity measurements in dried blood spot extracts can reliably detect infantile Pompe disease in patients. The convenience of collecting and shipping dried blood specimens plus rapid turnaround time makes this assay an attractive alternative to established methods.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702880     DOI: 10.1097/01.gim.0000217781.66786.9b

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  21 in total

Review 1.  Newborn screening for neuropathic lysosomal storage disorders.

Authors:  Wuh-Liang Hwu; Yin-Hsiu Chien; Ni-Chung Lee
Journal:  J Inherit Metab Dis       Date:  2010-06-08       Impact factor: 4.982

2.  Genotype-phenotype correlation of 17 cases of Pompe disease in Spanish patients and identification of 4 novel GAA variants.

Authors:  Paula Hernández-Arévalo; José D Santotoribio; Rocío Delarosa-Rodríguez; Antonio González-Meneses; Salvador García-Morillo; Pilar Jiménez-Arriscado; Juan M Guerrero; Hada C Macher
Journal:  Orphanet J Rare Dis       Date:  2021-05-21       Impact factor: 4.123

Review 3.  Glycogen storage disease type II: clinical overview.

Authors:  M Di Rocco; D Buzzi; M Tarò
Journal:  Acta Myol       Date:  2007-07

4.  Enzyme analysis for Pompe disease in leukocytes; superior results with natural substrate compared with artificial substrates.

Authors:  O P van Diggelen; L F Oemardien; N A M E van der Beek; M A Kroos; H K Wind; Y V Voznyi; D Burke; M Jackson; B G Winchester; A J J Reuser
Journal:  J Inherit Metab Dis       Date:  2009-04-19       Impact factor: 4.982

5.  Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease.

Authors:  Na Lin; Jingyu Huang; Sara Violante; Joseph J Orsini; Michele Caggana; Erin E Hughes; Colleen Stevens; Lisa DiAntonio; Hsuan Chieh Liao; Xinying Hong; Farideh Ghomashchi; Arun Babu Kumar; Hui Zhou; Ruth Kornreich; Melissa Wasserstein; Michael H Gelb; Chunli Yu
Journal:  Clin Chem       Date:  2017-02-14       Impact factor: 8.327

Review 6.  Acid alpha-glucosidase deficiency (Pompe disease).

Authors:  Tokiko Fukuda; Ashley Roberts; Paul H Plotz; Nina Raben
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

7.  Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.

Authors:  Priya S Kishnani; Paula C Goldenberg; Stephanie L DeArmey; James Heller; Danny Benjamin; Sarah Young; Deeksha Bali; Sue Ann Smith; Jennifer S Li; Hanna Mandel; Dwight Koeberl; Amy Rosenberg; Y-T Chen
Journal:  Mol Genet Metab       Date:  2010-01       Impact factor: 4.797

8.  Long-term, high-level hepatic secretion of acid α-glucosidase for Pompe disease achieved in non-human primates using helper-dependent adenovirus.

Authors:  D P W Rastall; S S Seregin; Y A Aldhamen; L M Kaiser; C Mullins; A Liou; F Ing; C Pereria-Hicks; S Godbehere-Roosa; D Palmer; P Ng; A Amalfitano
Journal:  Gene Ther       Date:  2016-07-01       Impact factor: 5.250

Review 9.  Pompe disease: literature review and case series.

Authors:  Majed Dasouki; Omar Jawdat; Osama Almadhoun; Mamatha Pasnoor; April L McVey; Ahmad Abuzinadah; Laura Herbelin; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

10.  Reference intervals of α-glycosidase, β-glycosidase, and α-galactosidase in dried blood spot in a Turkish newborn population.

Authors:  Ozan Aldemir; Pelin Ergun; Sezgin Güneş; Ozge Altun Köroğlu; Mehmet Yalaz; Nilgün Kültürsay; Mahmut Coker; Eser Y Sözmen
Journal:  Eur J Pediatr       Date:  2013-05-10       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.